(NASDAQ: DYN) Dyne Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Dyne Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast DYN's revenue for 2026 to be $735,422,760, with the lowest DYN revenue forecast at $431,932,996, and the highest DYN revenue forecast at $1,038,912,523. On average, 5 Wall Street analysts forecast DYN's revenue for 2027 to be $11,804,956,125, with the lowest DYN revenue forecast at $2,835,981,121, and the highest DYN revenue forecast at $21,190,860,137.
In 2028, DYN is forecast to generate $42,624,512,084 in revenue, with the lowest revenue forecast at $37,623,637,318 and the highest revenue forecast at $49,102,825,030.